trial · primary record
Nebulized Ensifentrine Suspension; 3 mg
Non-cystic Fibrosis Bronchiectasis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 284 |
| Primary completion | 2027-09-24 |
| Primary endpoint | Rate of protocol-defined pulmonary exacerbations (number of events per subject-year) |
| Registry ID | NCT06559150 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:16.175Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06559150
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.